5 Best Biotech Stocks with Highest Upside Potential

2. Ocular Therapeutix Inc. (NASDAQ:OCUL)

Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the 10 best biotech stocks with highest upside potential.

On April 13, William Blair maintained an Outperform rating on Ocular Therapeutix (NASDAQ:OCUL) right after the presentation of additional SOL-1 clinical trial data. According to the firm, this post-hoc investigation unequivocally supports Axpaxli’s overall effectiveness and durability. In particular, starting at week 8, the treatment showed prolonged disease control over aflibercept, resulting in improvements in the median time to more than or equal to 30-micrometer and 75-micrometer increases in central subfield thickness at 23 and 22 weeks.

Additionally, patients with poorer initial baseline measurements showed higher treatment improvements, according to quartile analyses contextualizing visual acuity increases. The underlying safety characteristics are essentially unchanged. In addition to publishing detailed patient-level information about past intraocular inflammation instances, the company has said that drug particles that were first classified as vitreous floaters were totally resorbed after a 20-week mean duration.

William Blair reiterated that Sustained anatomic control is a crucial leading signal of vision loss and significantly influences therapy choices within this particular indication. Based only on these stand-alone SOL-1 trial findings, the company is now moving closer to submitting a formal New Drug Application.

Ocular Therapeutix Inc. (NASDAQ:OCUL) focuses on developing and commercializing therapeutics for different eye conditions, including retinal diseases, using its bioresorbable hydrogel-based formulation technology. Its portfolio includes DEXTENZA, AXPAXLI in phase 3 of clinical trial, and OTX-TIC in phase 2 of clinical trial.